To evaluate the plasma trough concentrations (Ctrough) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.
Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis
MARINARO, Letizia;ARIAUDO, ALESSANDRA;D'AVOLIO, ANTONIO;BONORA, Stefano;
2017-01-01
Abstract
To evaluate the plasma trough concentrations (Ctrough) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
dkw492.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
153.15 kB
Formato
Adobe PDF
|
153.15 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
